Neurodevelopmental Impact of Treatment in Hypothyroxinaemia of Prematurity.

CompletedOBSERVATIONAL
Enrollment

373

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

July 1, 2021

Study Completion Date

September 1, 2022

Conditions
Transient Hypothyroxinemia of Prematurity
Interventions
DRUG

L-thyroxine at a dose of 7.5 µg/kg/d for THOP

Subjects diagnosed with THOP (as previously defined) and treated with L-thyroxine at a dose of 7.5 µg/kg/d are less likely to have an impaired ASQ score at 4 years of corrected age.

OTHER

THOP without treatment

Subjects diagnosed with THOP (as previously defined) and who received no L-thyroxine treatment.

OTHER

NoTHOP

Subjects diagnosed no-THOP (as previously defined)

Trial Locations (3)

38100

CHU Grenoble, Grenoble

42000

CHU Saint EtienneHopital, Saint-Etienne

69300

HFME, Bron

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT06346236 - Neurodevelopmental Impact of Treatment in Hypothyroxinaemia of Prematurity. | Biotech Hunter | Biotech Hunter